ORIC Pharmaceuticals
ORIC | NASDAQ
$7.52
-$0.34 (-4.33%)
At close: Nov 16, 2026, 4:00 PM ET
$7.53
+$0.01 (+0.13%)
After-hours:
Nov 16, 2026, 6:42 PM ET
ORIC Pharmaceuticals Company Profile
Company profile explainedCompany Profile
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Jacob Chacko | President, Chief Executive Officer & Director |
| Dominic G. Piscitelli | Chief Financial Officer |
| Charles L. Sawyers | Founder & Member of Scientific Advisory Board |
| Christian V. Kuhlen | General Counsel |
| Daniel Iazzetti | Vice President & Head of People |
| Edna Chow Maneval | Executive Vice President of Clinical Development |
| Kevin Brodbeck | Chief Technical Officer |
| Lori Sickels Friedman | Chief Scientific Officer |
| Pratik S. Multani | Chief Medical Officer |
| Richard A. Heyman | Founder, Independent Chairman & Member of Scientific Advisory Board |
| Scott W. Lowe | Founder & Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 8-K | Current Report |
| Oct 21, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 26, 2026 | 144 | Filing |
| Aug 03, 2026 | 10-Q | Quarterly Report |
| Aug 03, 2026 | 8-K | Current Report |
| Jul 30, 2026 | S-8 | Filing |
ORIC Pharmaceuticals
| Country | United States |
| IPO Date | Apr 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Jacob Chacko |
Contact Details
240 East Grand Avenue South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | ORIC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001796280 |
| CUSIP Number | 68622P109 |
| ISIN Number | US68622P1093 |
| SIC Code | 2834 |
Recent News
- 24 days ago / seekingalpha.comORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript
- 25 days ago / marketbeat.comOric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study
- 25 days ago / globenewswire.comORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
- 25 days ago / globenewswire.comORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
- 29 days ago / globenewswire.comORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
- 1 month ago / globenewswire.comORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
- 2 months ago / globenewswire.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 2 months ago / seekingalpha.comORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 3 months ago / globenewswire.comORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- 4 months ago / globenewswire.comORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Add to Watchlist
Select watchlists to add or remove ORIC